FDA authorizes new e-cigarette products, citing adult smoking cessation data; lawmakers criticize the decision
The FDA recently authorized new e-cigarette products after a review process of 615 days, more than three times the 180-day statutory deadline. The agency cited data showing 20% to 35% of adult smokers using a tobacco-flavored pod had stopped smoking cigarettes entirely at six weeks, with menthol pod figures ranging from roughly 28% to nearly 50%. Some members of Congress criticized the decision.
Single source · Not corroborated
The Food and Drug Administration granted marketing authorization to new e-cigarette products, concluding that permitting their sale is "appropriate for the protection of the public health" under the standard established by the Family Smoking Prevention and Tobacco Control Act of 2009. The agency published data indicating that adults who switched fully to the authorized products showed lower exposure to harmful chemicals than those who continued smoking combustible cigarettes.
The review took 615 days to complete — more than three times the 180-day deadline Congress set for Premarket Tobacco Product Application reviews. The Washington Examiner's op-ed noted that while the delay has real costs, including an opportunity for illicit products to dominate the market, the thoroughness of the review was difficult to criticize on scientific grounds. The authorization brings the total number of FDA-cleared e-cigarette products to approximately four dozen, according to the Examiner.
Critics of the decision, including Rep. Raja Krishnamoorthi (D-IL), said the FDA "should be cracking down on products that hook kids on nicotine." The Examiner noted that such criticism did not include a specific rebuttal to the agency's scientific findings or the methodology used in the review. The FDA's authorization did not classify the products as smoking cessation aids; it assessed only whether marketing them serves the public health under the statutory cost-benefit framework.